After both colon and tnbc, I’m not sure how much other pre-clinical cancer data adds. You have an MOA possible explanation now with the two different cancers. So I understand doing NASH over another cancer with limited resources. My thoughts would be as resources become available do a MS p2 ind next. Don’t they already have the animal data for MS, can’t remember off-hand?